These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 9371346)

  • 1. Exposure-response relationships for saquinavir, zidovudine, and zalcitabine in combination therapy.
    Vanhove GF; Gries JM; Verotta D; Sheiner LB; Coombs R; Collier AC; Blaschke TF
    Antimicrob Agents Chemother; 1997 Nov; 41(11):2433-8. PubMed ID: 9371346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of saquinavir, zidovudine, and zalcitabine in combination therapy.
    Vanhove GF; Kastrissios H; Gries JM; Verotta D; Park K; Collier AC; Squires K; Sheiner LB; Blaschke TF
    Antimicrob Agents Chemother; 1997 Nov; 41(11):2428-32. PubMed ID: 9371345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group.
    Collier AC; Coombs RW; Schoenfeld DA; Bassett RL; Timpone J; Baruch A; Jones M; Facey K; Whitacre C; McAuliffe VJ; Friedman HM; Merigan TC; Reichman RC; Hooper C; Corey L
    N Engl J Med; 1996 Apr; 334(16):1011-7. PubMed ID: 8598838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality of life outcomes of combination zalcitabine-zidovudine, saquinavir-zidovudine, and saquinavir-zalcitabine-zidovudine therapy for HIV-infected adults with CD4 cell counts between 50 and 350 per cubic millimeter. PISCES (SV14604) Study Group.
    Revicki DA; Moyle G; Stellbrink HJ; Barker C
    AIDS; 1999 May; 13(7):851-8. PubMed ID: 10357386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality of life outcomes of saquinavir, zalcitabine and combination saquinavir plus zalcitabine therapy for adults with advanced HIV infection with CD4 counts between 50 and 300 cells/mm3.
    Revicki DA; Swartz C; Wu AW; Haubrich R; Collier AC
    Antivir Ther; 1999; 4(1):35-44. PubMed ID: 10682127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance mutations to zidovudine and saquinavir in patients receiving zidovudine plus saquinavir or zidovudine and zalcitabine plus saquinavir in AIDS clinical trials group 229.
    Schapiro JM; Lawrence J; Speck R; Winters MA; Efron B; Coombs RW; Collier AC; Merigan TC
    J Infect Dis; 1999 Jan; 179(1):249-53. PubMed ID: 9841849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized controlled trial of a protease inhibitor (saquinavir) in combination with zidovudine in previously untreated patients with advanced HIV infection.
    Vella S; Lazzarin A; Carosi G; Sinicco A; Armignacco O; Angarano G; Andreoni M; Tambussi G; Chiodera A; Floridia M; Scaccabarozzi S; Facey K; Duncan I; Boudes P; Bragman K
    Antivir Ther; 1996 Aug; 1(3):129-40. PubMed ID: 11322246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zalcitabine. An update of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of HIV infection.
    Adkins JC; Peters DH; Faulds D
    Drugs; 1997 Jun; 53(6):1054-80. PubMed ID: 9179531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection. A randomized, double-blind, placebo-controlled trial. North American HIV Working Party.
    Bartlett JA; Benoit SL; Johnson VA; Quinn JB; Sepulveda GE; Ehmann WC; Tsoukas C; Fallon MA; Self PL; Rubin M
    Ann Intern Med; 1996 Aug; 125(3):161-72. PubMed ID: 8686973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy and tolerance of a combination of AZT, DDC, and saquinavir in patients infected with the human immunodeficiency virus].
    Soriano Vázquez V; Rodríguez-Rosado Martínez-Echevarría R; Jiménez-Nacher I; Valencia Ortega E; Moreno Celda V; González-Lahoz J
    Rev Clin Esp; 1998 Sep; 198(9):634-5. PubMed ID: 9803794
    [No Abstract]   [Full Text] [Related]  

  • 11. Evaluation of pharmacokinetics, safety, tolerance, and activity of combination of zalcitabine and zidovudine in stable, zidovudine-treated pediatric patients with human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 190 Team.
    Bakshi SS; Britto P; Capparelli E; Mofenson L; Fowler MG; Rasheed S; Schoenfeld D; Zimmer B; Frank Y; Yogev R; Jimenez E; Salgo M; Boone G; Pahwa SG
    J Infect Dis; 1997 May; 175(5):1039-50. PubMed ID: 9129064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Saquinavir. A review of its pharmacology and clinical potential in the management of HIV infection.
    Noble S; Faulds D
    Drugs; 1996 Jul; 52(1):93-112. PubMed ID: 8799687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Saquinavir hard gel suppresses viral load insufficiently in HIV-infected patients naive to anti-retroviral therapy: a retrospective cohort study.
    Jensen-Fangel S; Kirk O; Larsen L; Blaxhult A; Gerstoft J; Pedersen C; Black FT; Lundgren JD; Obel N
    Scand J Infect Dis; 1999; 31(5):489-93. PubMed ID: 10576129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized trial comparing saquinavir soft gelatin capsules versus indinavir as part of triple therapy (CHEESE study).
    Cohen Stuart JW; Schuurman R; Burger DM; Koopmans PP; Sprenger HG; Juttmann JR; Richter C; Meenhorst PL; Hoetelmans RM; Kroon FP; Bravenboer B; Hamann D; Boucher CA; Borleffs JC
    AIDS; 1999 May; 13(7):F53-8. PubMed ID: 10357371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zidovudine monotherapy versus zidovudine plus zalcitabine combination therapy in HIV-positive persons with CD4 cell counts 300-500 cells/mm3: a double-blind controlled trial. The M50003 Study Group Coordinating and Writing Committee.
    Moyle GJ; Bouza E; Antunes F; Smith D; Harris R; Warburg M; Walker M
    Antivir Ther; 1997 Dec; 2(4):229-36. PubMed ID: 11327442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of response to treatment and HIV genotypic changes during phase III trials with saquinavir and reverse transcriptase inhibitor combination therapy.
    Race E; Gilbert SM; Sheldon JG; Rose JS; Moffatt AR; Sitbon G; Dissanayeke SR; Cammack N; Duncan IB
    AIDS; 1998 Aug; 12(12):1465-74. PubMed ID: 9727567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial. The National Virology Groups. Delta Virology Working Group and Coordinating Committee.
    Brun-Vézinet F; Boucher C; Loveday C; Descamps D; Fauveau V; Izopet J; Jeffries D; Kaye S; Krzyanowski C; Nunn A; Schuurman R; Seigneurin JM; Tamalet C; Tedder R; Weber J; Weverling GJ
    Lancet; 1997 Oct; 350(9083):983-90. PubMed ID: 9329513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increase in neutralizing antibody titer against sequential autologous HIV-1 isolates after 16 weeks saquinavir (Invirase) treatment.
    Sarmati L; Nicastri E; el-Sawaf G; Ventura L; Salanitro A; Ercoli L; Vella S; Andreoni M
    J Med Virol; 1997 Dec; 53(4):313-8. PubMed ID: 9407377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multicentre study to determine the efficacy and tolerability of a combination of nelfinavir (VIRACEPT), zalcitabine (HIVID) and zidovudine in the treatment of HIV infected Nigerian patients.
    Idoko JA; Akinsete L; Abalaka AD; Keshinro LB; Dutse L; Onyenekwe B; Lhekwaba A; Njoku OS; Kehinde MO; Wambebe CO
    West Afr J Med; 2002; 21(2):83-6. PubMed ID: 12403023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of HIV infection in Nigeria with zalcitabine in combination with saquinavir mesylate: preliminary findings.
    Akinsete I; Njoku OS; Okanny CC; Chukwuani CM; Akanmu AS;
    West Afr J Med; 2000; 19(4):265-8. PubMed ID: 11391837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.